Literature DB >> 6098513

Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol.

B K Colasanti, R E Brown, C R Craig.   

Abstract

Marihuana extract containing 21.3% delta-9-tetrahydrocannabinol (100 micrograms/hr), delta-9-tetrahydrocannabinol (20 micrograms/hr), cannabidiol (20 micrograms/hr), or the polyethylene glycol vehicle (1 microliter/hr) was delivered topically to cat eyes via osmotic minipumps over a 9-day period. Intraocular pressure differences between treated and untreated eyes of cats receiving marihuana extract remained 3-4 mmHg lower than those for vehicle controls, while differential values for the delta 9-THC-treated group remained reduced by 3-5 mmHg; data for these two groups did not differ statistically. Pressure differences between treated and untreated eyes of cats receiving cannabidiol were likewise 3-4 mmHg lower than values for controls. Ocular toxicity after delta 9-THC, consisting of conjunctival erythema and chemosis as well as corneal opacification, was quite severe. Although these changes also occurred after marihuana extract, their intensity was much reduced. In contrast, no ocular toxicity became apparent during administration of cannabidiol. While marihuana extract and delta 9-THC produced a dose-related increase in the appearance of 8-13 Hz polyspike discharges in the electrocorticograms of rats, both polyethylene glycol and cannabidiol lacked this effect. These results indicate that the ocular and central effects of marihuana extract and delta 9-THC are qualitatively similar. In addition, it appears that the ocular hypotensive effect produced by cannabidiol is relatively dissociable from both the ocular toxicity and the neurotoxicity associated with marihuana extract.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6098513     DOI: 10.1016/0306-3623(84)90202-7

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  9 in total

1.  Effects of cannabidiol in animal models predictive of antipsychotic activity.

Authors:  A W Zuardi; J A Rodrigues; J M Cunha
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 3.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.

Authors:  Matt H Oltmanns; Sandeep S Samudre; Ivan G Castillo; Alireza Hosseini; Aron H Lichtman; Robert C Allen; Frank A Lattanzio; Patricia B Williams
Journal:  J Ocul Pharmacol Ther       Date:  2008-02       Impact factor: 2.671

5.  The Effects of Cannabidiol on Aqueous Humor Outflow and Trabecular Meshwork Cell Signaling.

Authors:  Alyssa S Aebersold; Zhao-Hui Song
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

Review 6.  Cannabinoids in health and disease.

Authors:  Natalya M Kogan; Raphael Mechoulam
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 7.  Epipremnum aureum Keratopathy: Case Report and Review of the Literature.

Authors:  Adam K Cohen; Despoina Theotoka; Anat Galor
Journal:  Eye Contact Lens       Date:  2020-09       Impact factor: 3.152

8.  Safety and tolerability of escalating cannabinoid doses in healthy cats.

Authors:  Justyna E Kulpa; Lina J Paulionis; Graham Ml Eglit; Dana M Vaughn
Journal:  J Feline Med Surg       Date:  2021-03-26       Impact factor: 2.015

9.  Cannabidiol Signaling in the Eye and Its Potential as an Ocular Therapeutic Agent.

Authors:  Alyssa Aebersold; Max Duff; Lucy Sloan; Zhao-Hui Song
Journal:  Cell Physiol Biochem       Date:  2021-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.